Сочетанная лучевая терапия, как альтернатива хирургическому лечению при местно-распространенном раке предстательной железы

Автор: Каприн А.Д., Хмелевский Е.В., Семин А.В.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Статья в выпуске: 1 т.8, 2008 года.

Бесплатный доступ

В настоящее время нет единого мнения о тактике лечения местно-распространенного рака предстательной железы. Эффективность стандартных методов лечения значительно уступает аналогичным показателям в группе локализованного рака предстательной железы. В данной работе собраны данные современных подходов лечения этой группы пациентов. Сочетанная лучевая терапия является методом выбора у больных этой группы. Применение последней, позволяет достичь высоких результатов и добиться полного контроля над опухолью, в независимости от степени местного распространения.

Местнораспространенный рак предстательной железы, брахитеапия, лучевая терапия, сочетанная лучевая терапия

Короткий адрес: https://sciup.org/14955138

IDR: 14955138

Список литературы Сочетанная лучевая терапия, как альтернатива хирургическому лечению при местно-распространенном раке предстательной железы

Велиев Е.И. Петров В.Б. Рак предстательной железы: диагностика и результаты хирургического лечения локализованных и местнораспространенных форм.//Русский медицинский журнал./2001. -т.9., №13-14. -С.564-568
Walsh P.С. Detectable PSA after surgery for prostate cancer: what I tell my patients.//AUA NEWS -September/October 1999. -Р. 25.
Zincke H., Osterling J.E., Blute M.L. et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.//J Urol.-1994.-152.-18.-50-57
Brewster S.F., Oxley J.D., Trivella M., Abbott C.D. Preoperative p53, bcl -2, CD44 and e-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.//J.Urol. -1999. -Vol. 161, №4. -Р.1238-1243.
Editorial: new methods for predicting extracapsular extension before surgery for prostate cancer//J. Urol. -1999. -Vol. 162, №4. -Р. 1359 -1360.
Zietman A.L., Dallow K.C., McManus P.L., Heney N.M., Shipley W.U. Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. Urology 1996; 47: 236-239.
Epstein J.I., CarMichael M., Walsh P.S. Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade and margins of resection to prognosis//J.Urol.-1993.-Vol. 149.-P.1040-1046
Gilliland F.D., Hoffman R.M., Hamilton A., Albertsen P., Eley J.W., Harlan L., Stanford J.L., Hunt W.C., Potosky A. Predicting extracapsular extension of prostate cancer in men treated with radical prostatectomy: results from the population based prostate cancer outcomes study//J. Urol. -1999. -Vol. 162, №4. -Р. 1341 -1345.
Bagshaw M.A. et al. Linear accelerator supervoltage YII. Carcinoma of the prostate.//Radiology.-1965.-85.
Bagshaw M.A. et al. Radiotherapy of prostatic carcinoma: long-or short-term efficacy.//Urology (Suppl.).-1985.-25.-17.
Brachman D.G., Thomas T., Hilbe J., Beyer D.C. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice.//Int J Radiat Oncol Biol Phys.-2000 Aug.-1.-48(1).-111-7.
Griffin TW, Krall JM & Russell KJ, Fast neutron irradiation of locally advanced prostate cancer. Seminars in Oncology. 1988;15(4): 359-365.
Barendsen GW, Koot CJ & VanKersen GR, The effect of oxygen on impairment of the proliferative capacity of human cells in culture by ionizing radiation of different LET. Int. J. Radiation Biology. 1966;10: 317-327.
Yonemoto L.T., Slater J.D., Rossi C.J. Jr et al. Combined proton and photon conformal radiation therapy for locally advanced carcinoma of the prostate: preliminary results of a phase I/II study.//Int J Radiat Oncol Biol Phys. -1997 Jan.-1.-37(1).-21-9.
Zietman A.L., DeSilvio M.L., Slater J.D. et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.//JAMA.-2005 Sep.-14.-294(10).-127.-4-6.
Nihei K., Ogino T., Ishikura S. et al. Phase II Feasibility Study of High-Dose Radiotherapy for Prostate Cancer Using Proton Boost Therapy: First Clinical Trial of Proton Beam Therapy for Prostate Cancer in Japan.//Jpn J Clin Oncol. -2005 Dec.-35(12).-745-52.
Slater J.D., Yonemoto L.T., Rossi C.J. Jr et al. Conformal proton therapy for prostate carcinoma//Int J Radiat Oncol Biol Phys. -1998 Sep.-1.-42(2)-299-304.
Stokes S.H. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation.//Int J Radiat Oncol Biol Phys.-2000 Apr.-1.-47(1).-129-36.
Pasteau O, Traitement du cancer de la prostate par le radium. Review du Maladies et Nutrition. 1911; 363-367
Denning CL, Carcinoma of the prostate seminal vesicles treated with radium. Surgery Gynaecology Obstetrics. 1922;34:99.
Young HH, Technique of radium treatment of cancer of prostate in seminal vesicles. Surgery Gynaecology Obstetrics. 1922;34:93.
Flocks RH, Kerr HD, Elkins HB & Culp DA, The treatment of carcinoma of the prostate by interstitial radiation with radioactive gold: a follow-up report. J. Urology. 1959; 71: 628.
Martinez A, Benson RC, Edmundson EK & Brindle J, Pelvic lymphadenectomy combined with transperineal interstitial implantation of iridium-192 and external beam radiotherapy for locally advanced prostate carcinoma: technical description. Int. J. Radiation Oncology Biology & Physics. 1985;11: 841-847.
Freiha FS & Bagshaw MA, Carcinoma of the prostate: results of post-irradiation biopsy. Prostate. 1984; 5: 19-25.
Ragde H., Elgamal A.A., Snow P.B. et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma.//Cancer.-1998 Sep.-1.-83(5).-989-1001.
Singh A.M., Gagnon G., Collins B. et al. Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: results of a matched pair analysis.//Prostate.-2005 Jan.-1.-62(1).-54-60.
Stone N.N., Stock R.G. Prostate Brachytherapy; Treatment Strategies//J Urol.-1999-Vol 162: 421-426.
Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate-to high-risk prostate cancer treated with permanent radioactive seed implantation.//Int J Radiat Oncol Biol Phys. 2002 Feb 1; 52(2):444-52.
Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, Dayes IS, et al. Randomized trial comparing Iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol. 2005; 23(6): 1192-9.
Potters L, Morgenstern C, Calugaru E, Fearn P, Jassal A, Presser J, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005 May; 173(5):1562-6.
Sylvester J, Grimm PD, Blasko JC, Millar J, Orio RF, Skoglund S, et al. 15-Year Biochemical Relapse Free Survival in Clinical Stage T1-T3 Prostate Cancer following Combined External Beam Radiotherapy and Brachytherapy; Seattle Experience. Int J Radiation Oncology Biol Phys.2007; 67(1):57-64.

Еще

Статья научная